Overview

A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)

Status:
Completed

Trial end date:
2016-10-05

Target enrollment:

Participant gender:

Summary

This Phase II study evaluated the safety and efficacy of LDE225 in adult and pediatric patients with Hh-pathway activated, relapsed MB.

Phase:

Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals